Yestino - The Signal · This GLP-1https://yestino.com/zh-CN/entities/this-glp-1-1e6126与 This GLP-1 相关的全部事件zh-CNThis GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a monthhttps://yestino.com/zh-CN/events/this-glp-1-drug-helped-people-maintain-their-weight-loss-in-c462c6https://yestino.com/zh-CN/events/this-glp-1-drug-helped-people-maintain-their-weight-loss-in-c462c6Tue, 22 Sep 2026 15:46:00 GMTViking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. 来源：MarketWatch